お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:コンパニオン診断の世界市場:診断技術の将来像 (資金源別・用途別)、カスタム型の予測/分析、昨今のCOVID-19の影響、エグゼクティブ/コンサルタント向け提言 (2021年~2025年)
市場調査レポート
商品コード
999392

コンパニオン診断の世界市場:診断技術の将来像 (資金源別・用途別)、カスタム型の予測/分析、昨今のCOVID-19の影響、エグゼクティブ/コンサルタント向け提言 (2021年~2025年)

Companion Diagnostic Markets - The Future of Diagnostics. By Funding Source and Application with Customized Forecasting/Analysis, Covid Updates, and Executive and Consultant Guides 2021-2025

出版日: | 発行: Howe Sound Research | ページ情報: 英文 455 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.46円
コンパニオン診断の世界市場:診断技術の将来像 (資金源別・用途別)、カスタム型の予測/分析、昨今のCOVID-19の影響、エグゼクティブ/コンサルタント向け提言 (2021年~2025年)
出版日: 2021年04月02日
発行: Howe Sound Research
ページ情報: 英文 455 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

コンパニオン診断は、診断業界に革命を起こそうとしてます。最近になって市場はようやく研究室から診療所に移りつつあり、腫瘍診断 (特に免疫腫瘍学) で普及が先行しています。FDA (米国食品医薬品局) では、この診断技術への参入・発展を今後も推奨しようとしています。しかし、 新型コロナウイルス感染症 (COVID-19) がこの市場にも悪影響を及ぼしており、特殊がん検査の需要が減少しています。

当レポートでは、世界のコンパニオン診断市場の最新情勢と将来展望について分析し、市場の基本構造や主な促進・抑制要因、昨今の市場の主な動き、主要企業のプロファイルと昨今の事業展開状況、市場規模・価格水準の動向見通し、地域別・用途別・資金源別の詳細動向、今後の市場発展の方向性、といった情報を取りまとめてお届けいたします。

目次

第1章 市場ガイド

  • コンパニオン診断市場:戦略的状況分析
  • エグゼクティブ・マーケティング・販売・ビジネス開発スタッフ向け提言
  • 経営コンサルタント・投資顧問向け提言

第2章 イントロダクション・市場定義

  • コンパニオン診断とは何か?
  • 個別化医療革命
  • 市場の定義
    • 市場収益額・市場規模
  • 分析手法
  • 臨床検査向け支出額の見通し
    • 米国の臨床検査向け医療費支出額

第3章 市場概要

  • ダイナミックな市場の参入企業
    • 教育・研究機関
    • 診断検査の開発者
    • 医療機器のサプライヤー
    • 試薬の流通業者・サプライヤー
    • 独立系検査室
    • 国公立/地域検査室
    • 病院検査室
    • 開業医向け検査室
    • 監査機関
    • 認証機関
  • 個別化医療とコンパニオン診断
    • 基本
    • 方法
    • 疾病のリスク評価
    • 用途
    • 診断と介入
    • 医薬品の開発と使用法
    • 呼吸プロテオミクス
    • がんゲノミクス
    • 集団検診
    • 課題
    • 規制の監視
    • 知的財産権
    • 償還方針
    • 患者のプライバシーと守秘義務
  • 染色体・遺伝子・エピジェネティクス
    • 染色体
    • 遺伝子
    • エピジェネティクス
  • がん遺伝子
    • 生殖細胞系列と体細胞型
    • 臨床的役割の変化
  • 産業構造が果たす役割
    • 新規医薬品向け資金調達の市場
    • 規模の経済性
    • 開業医向け検査室
    • 医師とPOCT (ポイントオブケア検査)

第4章 市場動向

  • 成長の促進要因
    • 医療水準
    • 免疫腫瘍学
    • 法的責任
    • 高齢人口
  • 成長の抑制要因
    • 知識の状態
    • 「遺伝子のブリザード」
    • プロトコル抵抗
    • 規制と適用範囲
  • 計装と自動化
    • 市場シェアの鍵となる診断装置
    • バイオインフォマティクスが果たす役割
  • 診断技術の開発
    • 次世代シーケンシングによる革命の後押し
    • シングルセル・ゲノミクスによる状況の変化
    • 薬理ゲノミクスによる診断と治療の融合
    • CGES検査 - 勇敢な新世界
    • バイオチップ/巨大磁気抵抗ベースのアッセイ

第5章 コンパニオン診断:近年の進捗状況

  • 昨今の動向:当セクションの重要性と活用方法

第6章 主要企業のプロファイル

  • 10x Genomics, Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc.
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd.
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

第7章 世界のコンパニオン診断市場

  • 世界市場の概要:国別
  • 世界市場の概要:用途別
  • 世界市場の概要:資金源別

第8章 世界のコンパニオン診断市場:用途別

  • 腫瘍
  • 神経症
  • 心臓病
  • その他

第9章 世界のコンパニオン診断市場:資金源別

  • 製薬企業
  • ベンチャー企業
  • 医療機関
  • その他

第10章 付録

図表

Table of Tables

  • Table 1 Lab Spending 2014 to 2024
  • Table 2 Market Players by Type
  • Table 3 The Base Pairs
  • Table 4 Five Factors Driving Growth
  • Table 5 Four Factors Limiting Growth
  • Table 6 Key Diagnostic Laboratory Technology Trends
  • Table 7 Next Generation Sequencing Technologies - Speed and Cost
  • Table 8 Global Companion Diagnostic Market by Region
  • Table 9 Global Market by Application
  • Table 10 Global Market by Funding Source
  • Table 11 Oncology by Country
  • Table 12 Neurology by Country
  • Table 13 Cardiology by Country
  • Table 14 Other Application by Country
  • Table 15 Pharmaceutical by Country
  • Table 16 Venture by Country
  • Table 17 Clinical by Country
  • Table 18 Other Funding by Country
  • Table 19 2021 Clinical Laboratory Fee Schedule
  • Table 20 Pharmacogenomic Biomarkers

Table of Figures

  • Figure 1 FDA Approved Companion Diagnostics
  • Figure 2 Clinical Lab Spending 2014 to 2024
  • Figure 3 DNA Strands and Chromosomes
  • Figure 4 Karyogram of Human Chromosomes
  • Figure 5 Size of Various Genomes
  • Figure 6 Germline vs Somatic Mutations
  • Figure 7 Comparing Genomic Diagnostic and Traditional Testing
  • Figure 8 Percentage of World Population Over 65
  • Figure 9 Base Year Country Market Share Chart
  • Figure 10 CDx Market by Application - Base vs. Final Year
  • Figure 11 CDx Market by Application Base Year
  • Figure 12 CDx Market by Application Final Year
  • Figure 13 Application Type Share by Year
  • Figure 14 Funding Source - Base vs. Final Year
  • Figure 15 Funding Source Market Base Year
  • Figure 16 Funding Source Market Final Year
  • Figure 17 Funding Source Share by Year
  • Figure 18 Oncology Growth
  • Figure 19 Neurology Growth
  • Figure 20 Cardiology Growth
  • Figure 21 Other Application Growth
  • Figure 22 Pharmaceutical Growth
  • Figure 23 Venture Growth
  • Figure 24 Clinical Growth
  • Figure 25 Other Funding Growth
目次

OVERVIEW:

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Companion Diagnostic Market - Strategic Situation Analysis
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 What are Companion Diagnostics?
  • 2.2 The Personalized Medicine Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenue Market Size
  • 2.4 Methodology
    • 2.4.1 Authors
    • 2.4.2 Sources
  • 2.5 A Spending Perspective on Clinical Laboratory Testing
    • 2.5.1 U.S. Medicare Expenditures for Laboratory Testing

3 Market Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Instrumentation Supplier
    • 3.1.4 Distributor and Reagent Supplier
    • 3.1.5 Independent Testing Lab
    • 3.1.6 Public National/regional lab
    • 3.1.7 Hospital lab
    • 3.1.8 Physician Office Labs
    • 3.1.9 Audit Body
    • 3.1.10 Certification Body
  • 3.2 Personalized Medicine and Companion Diagnostics
    • 3.2.1 Basics
    • 3.2.2 Method
    • 3.2.3 Disease risk assessment
    • 3.2.4 Applications
    • 3.2.5 Diagnosis and intervention
  • 3.2.5.1 Companion Diagnostics
    • 3.2.6 Drug development and usage
    • 3.2.7 Respiratory proteomics
    • 3.2.8 Cancer genomics
    • 3.2.9 Population screening
    • 3.2.10 Challenges
    • 3.2.11 Regulatory oversight
    • 3.2.12 Intellectual property rights
    • 3.2.13 Reimbursement policies
    • 3.2.14 Patient privacy and confidentiality
  • 3.3 Chromosomes, Genes and Epigenetics
    • 3.3.1 Chromosomes
    • 3.3.2 Genes
    • 3.3.3 Epigenetics
  • 3.4 Cancer Genes
    • 3.4.1 Germline vs Somatic
    • 3.4.2 Changing Clinical Role
  • 3.5 Structure of Industry Plays a Part
    • 3.5.1 New Pharmaceutical Funding Market
    • 3.5.2 Economies of Scale
  • 3.5.2.1 Hospital vs. Central Lab
    • 3.5.3 Physician Office Labs
    • 3.5.4 Physicians and POCT

4 Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Level of Care.
    • 4.1.2 Immuno-oncology
    • 4.1.3 Liability
    • 4.1.4 Aging Population
  • 4.2 Factors Limiting Growth
    • 4.2.1 State of knowledge
    • 4.2.2 Genetic Blizzard
    • 4.2.3 Protocol Resistance
    • 4.2.4 Regulation and coverage
  • 4.3 Instrumentation and Automation
    • 4.3.1 Instruments Key to Market Share
    • 4.3.2 Bioinformatics Plays a Role
  • 4.4 Diagnostic Technology Development
    • 4.4.1 Next Generation Sequencing Fuels a Revolution
    • 4.4.2 Single Cell Genomics Changes the Picture.
    • 4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 4.4.4 CGES Testing, A Brave New World.
    • 4.4.5 Biochips/Giant magneto resistance based assay

5 Companion Diagnostics Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
  • 5.2 HTG Molecular Diagnostics 2020 Revenues Fall 56 Percent
  • 5.3 Oncocyte Details Expansions Plans
  • 5.4 Agilent Acquires Resolution Biosciences
  • 5.5 Qiagen, Inovio Expand CDx Partnership
  • 5.6 AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance
  • 5.7 NeoGenomics to Grow Through CDx Agreements, Acquisitions
  • 5.8 Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction
  • 5.9 Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
  • 5.10 FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies
  • 5.11 Promega to Develop MSI Assay as CDx
  • 5.12 HTG Molecular Q2 Revenues Drop 66 Percent
  • 5.13 Guardant Health to Develop CDx for Janssen
  • 5.14 Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx
  • 5.15 FDA Approval for FoundationOne®CDx
  • 5.16 FDA finalizes CDx Guidance
  • 5.17 QIAGEN Launches CDx Therascreen BRAF Test
  • 5.18 Myriad Genetics Seeks Approval for Companion Diagnostic
  • 5.19 ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx
  • 5.20 QIAGEN Builds on Global Collaboration with Amgen
  • 5.21 Foundation Medicine nabs 19th companion Dx
  • 5.22 Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostics
  • 5.23 Myriad Wins Japanese Approval for BRACAnalysis
  • 5.24 Fujitsu Improves Efficiency in Cancer Genomic Medicine
  • 5.25 Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
  • 5.26 Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
  • 5.27 Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer
  • 5.28 Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic
  • 5.29 Universal Genetic Testing for All Breast Cancer Patients
  • 5.30 Exact Sciences buys Genomic Health
  • 5.31 Biodesix Highlights Pipeline and Companion Diagnostic Development

6 Profiles of Key Players

  • 6.1 10x Genomics, Inc
  • 6.2 Abbott Diagnostics
  • 6.3 AccuraGen Inc.
  • 6.4 Adaptive Biotechnologies
  • 6.5 Aethlon Medical
  • 6.6 Agena Bioscience, Inc.
  • 6.7 Agilent
  • 6.8 Anchor Dx
  • 6.9 ANGLE plc
  • 6.10 ApoCell, Inc.
  • 6.11 ArcherDx, Inc.
  • 6.12 ARUP Laboratories
  • 6.13 Asuragen
  • 6.14 AVIVA Biosciences
  • 6.15 Baylor Miraca Genetics Laboratories
  • 6.16 Beckman Coulter Diagnostics
  • 6.17 Becton, Dickinson and Company
  • 6.18 BGI Genomics Co. Ltd
  • 6.19 Bioarray Genetics
  • 6.20 Biocartis
  • 6.21 Biocept, Inc
  • 6.22 Biodesix Inc.
  • 6.23 BioFluidica
  • 6.24 BioGenex
  • 6.25 BioIVT
  • 6.26 Biolidics Ltd
  • 6.27 bioMérieux Diagnostics
  • 6.28 Bioneer Corporation
  • 6.29 Bio-Rad Laboratories, Inc
  • 6.30 Bio-Reference Laboratories
  • 6.31 Bio-Techne
  • 6.32 Bioview
  • 6.33 Bolidics
  • 6.34 Boreal Genomics
  • 6.35 Bristol-Myers Squibb
  • 6.36 Cancer Genetics
  • 6.37 Caris Molecular Diagnostics
  • 6.38 Castle Biosciences, Inc.
  • 6.39 CellMax Life
  • 6.40 Cepheid (now Danaher)
  • 6.41 Charles River Laboratories
  • 6.42 Chronix Biomedical
  • 6.43 Circulogene
  • 6.44 Clinical Genomics
  • 6.45 Cynvenio
  • 6.46 Cytolumina Technologies Corp.
  • 6.47 CytoTrack
  • 6.48 Datar Cancer Genetics Limited
  • 6.49 Diagnologix LLC
  • 6.50 Diasorin S.p.A.
  • 6.51 Enzo Life Sciences, Inc.
  • 6.52 Epic Sciences
  • 6.53 Epigenomics AG
  • 6.54 Eurofins Scientific
  • 6.55 Exosome Diagnostics
  • 6.56 Exosome Sciences
  • 6.57 Fabric Genomics
  • 6.58 Fluidigm Corp
  • 6.59 Fluxion Biosciences
  • 6.60 Foundation Medicine
  • 6.61 Freenome
  • 6.62 GeneFirst Ltd.
  • 6.63 Genetron Health (Beijing) Co., Ltd.
  • 6.64 Genomic Health
  • 6.65 GenomOncology
  • 6.66 GILUPI Nanomedizin
  • 6.67 Grail, Inc
  • 6.68 Guardant Health
  • 6.69 HalioDx
  • 6.70 HansaBiomed
  • 6.71 HeiScreen
  • 6.72 Helomics
  • 6.73 Horizon Discovery
  • 6.74 HTG Molecular Diagnostics
  • 6.75 iCellate
  • 6.76 Illumina
  • 6.77 Incell Dx
  • 6.78 Inivata
  • 6.79 Integrated Diagnostics
  • 6.80 Invivogen
  • 6.81 Invivoscribe
  • 6.82 Janssen Diagnostics
  • 6.83 MDNA Life SCIENCES, Inc
  • 6.84 MDx Health
  • 6.85 Menarini Silicon Biosystems
  • 6.86 Millipore Sigma
  • 6.87 Miltenyi Biotec
  • 6.88 MIODx
  • 6.89 miR Scientific
  • 6.90 Molecular MD
  • 6.91 MyCartis
  • 6.92 Myriad Genetics/Myriad RBM
  • 6.93 NantHealth, Inc.
  • 6.94 Natera
  • 6.95 NeoGenomics
  • 6.96 New Oncology
  • 6.97 Novogene Bioinformatics Technology Co., Ltd.
  • 6.98 Oncocyte
  • 6.99 OncoDNA
  • 6.100 Ortho Clinical Diagnostics
  • 6.101 Oxford Nanopore Technologies
  • 6.102 Panagene
  • 6.103 Perkin Elmer
  • 6.104 Personal Genome Diagnostics
  • 6.105 Personalis
  • 6.106 Precipio
  • 6.107 PrecisionMed
  • 6.108 Promega
  • 6.109 Qiagen Gmbh
  • 6.110 Rarecells SAS
  • 6.111 RareCyte
  • 6.112 Roche Molecular Diagnostics
  • 6.113 Screencell
  • 6.114 Sense Biodetection.
  • 6.115 Serametrix
  • 6.116 Siemens Healthineers
  • 6.117 Silicon Biosystems
  • 6.118 simfo GmbH
  • 6.119 Singlera Genomics Inc
  • 6.120 Singulomics
  • 6.121 SkylineDx
  • 6.122 Stratos Genomics
  • 6.123 Sysmex Inostics
  • 6.124 Tempus Labs, Inc.
  • 6.125 Thermo Fisher Scientific Inc
  • 6.126 Thrive Earlier Detection
  • 6.127 Todos Medical
  • 6.128 Trovagene
  • 6.129 Volition
  • 6.130 Vortex Biosciences

7 The Global Market for Companion Diagnostics

  • 7.1 Global Market Overview by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart - Global Market by Country
  • 7.2 Global Market by Application - Overview
    • 7.2.1 Table - Global Market by Application
    • 7.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 7.2.3 Chart - Global Market by Application - Base Year
    • 7.2.4 Chart - Global Market by Application - Final Year
    • 7.2.5 Chart - Global Market by Application - Share by Year
  • 7.3 Global Market Funding Source - Overview
    • 7.3.1 Table - Global Market by Funding Source
    • 7.3.2 Chart - Global Market Funding Source - Base/Final Year Comparison
    • 7.3.3 Chart - Global Market Funding Source - Base Year
    • 7.3.4 Chart - Global Market Funding Source - Final Year
    • 7.3.5 Chart - Global Market Funding Source - Share by Year

8 Global Companion Diagnostic Markets - By Application

  • 8.1 Oncology
    • 8.1.1 Table Oncology - by Country
    • 8.1.2 Chart - Oncology Growth
  • 8.2 Neurology
    • 8.2.1 Table Neurology - by Country
    • 8.2.2 Chart - Neurology Growth
  • 8.3 Cardiology
    • 8.3.1 Table Cardiology - by Country
    • 8.3.2 Chart - Cardiology Growth
  • 8.4 Other Application
    • 8.4.1 Table Other Application - by Country
    • 8.4.2 Chart - Other Application Growth

9 Global Companion Diagnostic Markets - Funding Source

  • 9.1 Global Market Pharmaceutical
    • 9.1.1 Table Pharmaceutical - by Country
    • 9.1.2 Chart - Pharmaceutical Growth
  • 9.2 Global Market Venture
    • 9.2.1 Table Venture - by Country
    • 9.2.2 Chart - Venture Growth
  • 9.3 Global Market Clinical
    • 9.3.1 Table Clinical - by Country
    • 9.3.2 Chart - Clinical Growth
  • 9.4 Global Market Other Funding
    • 9.4.1 Table Other Funding - by Country
    • 9.4.2 Chart - Other Funding Growth

10 Appendices

  • 10.1 United States Medicare System: January 2021 Clinical Laboratory Fees Schedule
  • 10.2 Pharmacogenomic Biomarkers in Drug Labeling
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.